Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind dose-finding study of pyrifazimine tablets in drug-resistant pulmonary tuberculosis
CTR20250660Phase 2Active
- Sponsor
- Beijing Union Pharmaceutical Factory No. 2
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfazimine in pulmonary tuberculosis (TB), Rifampicin-resistant pulmonary tuberculosis (RR-PTB), sponsored by Beijing Union Pharmaceutical Factory No. 2. Started Mar 2025; status: active.
02
Drugs
pirfazimine
03
Conditions
pulmonary tuberculosis (TB)Rifampicin-resistant pulmonary tuberculosis (RR-PTB)
Beyond the preview
Go deeper on CTR20250660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250660.